• Submitted by: manso
• Business and Economy
• 08 / 26 / 2011

---

After 15 years of development, Cuban state company Labiofam S.A. landed its first export deal for Vidatox, a tumor-fighting homeopathic medicine, the Cuban foreign ministry announced after Minsk-based PharmLand LLC agreed to market and distribute the product in Belarus.

Belarus is one stop in a Labiofam sales campaign throughout Europe. The company said the “commercial-scientific delegation” currently in Belarus also visited Russia, Ukraine and Kazakhstan to negotiate sales of Vidatox. Another Labiofam delegation is traveling to Bulgaria, Albania, Turkey, Croatia, Slovenia, Serbia and Hungary. Beginning Sept. 3, two other delegations will visit Great Britain, France, Denmark, Belgium, Germany, Switzerland, Netherlands, Spain and Portugal.

In addition to PharmLand, a Belarus-Dutch joint venture that is part of pharmaceutical state company Belbiopharm, a private clinic in Albania agreed to offer the product.

The company didn’t say why it didn’t include Italy in its marketing efforts. According to Cuban press reports, demand for Vidatox from foreign cancer patients, particularly Italians, has been “overwhelming” the company. The Cuban embassy in Rome put a notice on its Website last year, saying that “for now, unfortunately, it will not be possible to respond positively to the thousands of requests pouring in to Labiofam, since its production is still very limited.”

Vidatox, made from the venom of the blue scorpion, has anti-tumorial, analgesic and anti-inflammatory qualities that help improve the quality of life of cancer patients, according to Labiofam. The company presents the product as a “natural, complementary alternative in the treatment of oncological patients.”

Last year, PharmLand signed a contract with Cuban state company SIMAB on  joint production of anti-cancer drug nimotuzumab in Belarus.

Source: /www.cubastandard.com/2011/08/25/labiofam-makes-marketing-pitch-for-cancer-medicine-in-europe/